カテゴリ： GlobalData, ドイツ, 企業調査

Merck KGaA (MRK)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Merck KGaA (MRK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9990
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：307
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：ドイツ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Merck KGaA (Merck), a subsidiary of E. Merck KG, is a pharmaceutical and chemical company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis, and infertility and over-the-counter products for colds and pain; and develops liquid crystal mixtures, OLED materials and cosmetic active ingredients. The company also provides a wide range of products including lab water systems to gene editing tools, cell lines, antibodies and end-to-end systems. Merck serves healthcare, performance materials and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.

Merck KGaA (MRK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 9
List of Figures 12
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 13
Merck KGaA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 14
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 15
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 16
Merck KGaA, Medical Devices Deals, 2012 to YTD 2018 18
Merck KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 19
Merck KGaA, Pharmaceuticals & Healthcare, Deal Details 28
Asset Purchase 28
Merck KgaA Acquires SevenSeas Original Brand 28
Venture Financing 29
Sutro Biopharma Raises USD85.4 Million in Series E Financing 29
SerImmune Raises USD8 Million in Venture Financing 31
TocopheRx Raises US$3.3 Million In Seed Financing 32
Partnerships 33
Kyowa Hakko Kirin Enters into Agreement with Merck and Pfizer 33
Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 34
Accelerated Cure Project Enters into Co-Development Agreement with EMD Serono 35
Immutep Enters into Agreement with Merck and Pfizer 36
Checkmate Pharma Enters into Partnership with Merck and Pfizer 37
Leap Therapeutics Enters into Co-Development Agreement with Merck and Pfizer 38
Vyriad Enters into Collaboration Agreement with Merck and Pfizer 39
Merck Enters into Co-Development Agreement with Xian-Janssen Pharma 40
Merck Enters into Development Agreement with SFJ Pharma 41
Forty Seven Enters into Agreement with Merck 42
Merck Enters into Agreement with Avanti Lipids Polar 43
Neon Therapeutics Enters into Agreement with Merck 44
Orexigen Therapeutics Enters into Agreement with Merck KGaA 45
MilliporeSigma to Enter into Agreement with Samsung Biologics 46
Phosplatin Therapeutics Enters into Agreement with Pfizer and Merck 47
MilliporeSigma Enters into Agreement with Angiex 48
Merck Enters into Partnership with Angiex 49
Millipore Enter into Partnership with Baylor College of Medicine and Texas Children’s Hospital 50
Acino International Enters into Distribution Agreement with Merck 51
Cancer Research Technology Enters into Agreement with Merck 52
eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 53
SerImmune Enters into R&D Agreement with Merck 54
Human Longevity Enters into Agreement with Merck 55
F-star Biotech Enters into Partnership with Merck 56
EpiThany Enters into Agreement with Merck and Pfizer 57
VAXIMM Enters into Agreement with Merck and Pfizer 58
Avillion Enters into Co-Development Agreement with Merck 59
Merck Enters into Agreement with Palantir Technologies 60
EMD Serono Enters into Agreement with University of Texas MD Anderson Cancer Center 61
F. Hoffmann-La Roche Expands its Distribution Agreement with MilliporeSigma 62
Evotec Partners with Merck 63
BioMed X Enters into Agreement with Merck 64
Debiopharm Partners with Merck and Pfizer 65
Transgene Enters into Agreement with Merck and Pfizer 66
Vaccinex Enters into Agreement with Merck 67
PCAS Enters into Distribution Agreement with MilliporeSigma 68
MilliporeSigma Enters into Research Agreement with International Vaccine Institute 69
Selvita Enters into Agreement with Merck 70
Merck Enters into Agreement with University of Buea 71
Merck, Pfizer and Verastem Enter into Agreement 72
Merck Enters into Research Agreement with European Molecular Biology Labs 73
Merck, Pfizer and Syndax Pharma Enter into Agreement 74
Selvita Enters into Development and Commercialization Agreement with Merck 75
Biothera Pharma Expands Agreement with Merck 76
Sigma-Aldrich Enters into Agreement with Sanger Institute 77
Sigma-Aldrich Enters into Distribution Agreement with IROA Technologies 78
Nippon Shinyaku Enters into Co-Promotion Agreement with Merck Serono 79
Merck Serono Enters into Co-Development Agreement with Genea Biomedx and Illumina 80
Aeterna Zentaris Enters into Agreement with EMD Serono 81
Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 82
Lucigen Enters into Distribution Agreement with Sigma-Aldrich 83
Merck Serono Enters into Co-Development Agreement with MMV 84
Sigma-Aldrich Enters into Distribution Agreement with Roche 85
Merck Enters into Development Agreement with Precision Biologics 86
Indi Molecular Enters into Co-Development Agreement with Sigma-Aldrich 87
Pfizer Enters into Co-Development Agreement with Merck 88
BioSilta Enters into Co-Marketing Agreement with Sigma-Aldrich 90
Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 91
Hutchison China MediTech Enters into Co-Promotion Agreement with Merck Serono for Cardiovascular Drug Products 92
Merck Plans to Enter into Co-Development Agreement for Anti-PD-L1 93
Lupin Enters into Co-Development Agreement with Merck Serono 94
Merck Serono Extends R&D Agreement with San Raffaele 95
Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 96
Merck Serono Enters into Co-Development Agreement with Sysmex Inostics 97
Bionovis Enters into Agreement with Merck 98
EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 99
EMD Millipore Enters Into Co-Development Agreement With Promethera Biosciences 100
KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 101
Biopharm Enters Into Research Agreement With Merck Serono 102
Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 103
Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 104
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 105
Sigma-Aldrich Enters Into Distribution Agreement With Paragon Scientific 106
Gyros And EMD Millipore Enter Into Agreement To Develop And Commercialize Immunoassay Kits 107
Isu Abxis Enters into Co-Development Agreement with Merck 108
Luminex Extends Distribution Agreement With EMD Millipore 109
Alchemia Enters Into Collaboration Agreement with Merck Serono 110
Merck Serono Enters Into Clinical Development Agreement With Quintiles Transnational 111
Sigma Life Science Enters Into Distribution Agreement With The Culture Collections of Public Health England 112
Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 113
Merck Enters Into Co-Development Agreement With Nordic Bioscience For Sprifermin 114
Merck Serono Enters Into Co-Development Agreement With Feinstein Institute For Therapy Of Inflammatory Diseases 115
EMD Millipore Enters Into Co-Development Agreement With Sistemic For Stem Cell Markers 116
AB Sciex Enters Into Distribution Agreement With Sigma-Aldrich For Sciex Ichemistry Solutions 117
EMD Millipore Enters Into Co-Marketing Agreement With Julphar Diabetes For Recombinant Human Insulin 118
Sigma Life Science Expands Agreement With Autism Speaks To Develop Rat Models For Autism Research 119
Sigma Life Science Enters Into Co-Marketing Agreement With Axiogenesis 120
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 121
TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 122
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 124
Genovis Enters Into Distribution Agreement With Sigma-Aldrich 125
Dr. Reddy’s Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 126
EMD Millipore Enters Into Distribution Agreement With Ventria Bioscience 127
EMD Millipore Enters Into Co-Development Agreement With Centre for Commercialization of Regenerative Medicine 128
Mapi Pharma Amends Co-Development Agreement With Merck 129
TriLink BioTechnologies Enters Into Distribution Agreement With Sigma-Aldrich 130
Licensing Agreements 131
Isotopen Enters into Option Agreement to License for Folate Receptor with Merck 131
Merck Enters into Licensing Agreement with Nerviano Medical Sciences 132
Selexis Enters into Licensing Agreement with Merck KGaA 133
Merck Enters into Licensing Agreement with Domain Therapeutics 134
Merck Enters into Licensing Agreement with Vertex Pharma 135
Relief Therapeutics Enters into Licensing Agreement with Merck Serono 136
ObsEva Enters into Licensing Agreement with Merck Serono for OBE022 137
EMD Millipore Enters into Licensing Agreement with Singulex 138
Intrexon Enters into Licensing Agreement with Merck Serono 139
Allergopharma Enters into Licensing Agreement with S-TARget therapeutics 140
EMD Serono Amends its Licensing Agreement with Mersana Therapeutics 141
MorphoSys Enters into Licensing Agreement with Merck Serono 142
Merck Enters Into Licensing Agreement With Spanish National Cancer Research Centre 143
Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 144
ObsEva Enters Into Licensing Agreement With Merck Serono 145
Plasticell Enters Into Licensing Agreement With EMD Millipore For Xeno-Free Osteogenic Medium 146
Merck Enters into Licensing Agreement with Weizmann Institute of Science 147
Qualyst Transporter Solutions Enters into Licensing Agreement with BioReliance 148
Sigma Life Science Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 149
EMD Serono Enters into Licensing Agreement with Sutro Biopharma 150
Sage Labs Enters Into Licensing Agreement With Caribou Biosciences 151
Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 152
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 153
Sigma-Aldrich Enters Into Licensing Agreement With Scripps Research Institute For Research Reagents 155
Cellular Dynamics Enters Into Licensing Agreement With Life Technologies And Sigma-Aldrich 156
Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 157
Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 158
EMD Millipore Enters Into Licensing Agreement With iPS Academia For Stem Cell Patents 159
Materia Extends Licensing Agreement With Sigma Aldrich 160
PDS Biotechnology Enters Into Licensing Agreement With Merck For Versamune 161
Ligand Pharma Enters Into Licencing Agreement With Merck 162
Sigma-Aldrich Enters Into Licensing Agreement With University of Illinois 163
EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 164
Sigma Life Science Enters Into Licensing Agreement With Kyoto University 165
Equity Offering 166
KalVista Pharma Raises USD9.1 Million in Private Placement of Shares 166
iOnctura Spin Out from Merck and Cancer Research Technology 167
Debt Offering 168
Merck Raises USD801.4 Million in Private Placement of 0.23% Bonds Due 2017 168
Merck Raises USD916 Million in Private Placement of 0.75% Bonds Due 2019 169
Merck Raises USD629.7 Million in Private Placement of 1.375% Bonds Due 2022 170
Merck Raises USD1 Billion in Private Placement of 2.95% Notes Due 2022 171
Merck Raises USD750 Million in Private Placement of 2.4% Notes Due 2020 172
Merck Raises USD400 Million in Private Placement of 1.7% Notes Due 2018 173
Merck Raises USD250 Million in Private Placement of Floating Rate Notes Due 2017 174
Merck Raises USD1.6 Billion in Private Placement of 3.25% Notes Due 2025 175
Merck Raises USD1.2 Billion in Private Placement of 2.625% Bonds Due 2074 176
Merck Raises USD614 Million in Private Placement of 3.375% Bonds Due 2074 177
Asset Transactions 178
Procter & Gamble Receives Approval to Acquire 51.8% Stake in Consumer Health Business from Merck for USD4.2 Billion 178
Fresenius Acquires Biosimilars Business from Merck for USD703 Million 180
Zydus Healthcare Acquires Six Brands from Merck 181
Martin Dow Acquires Merck Operations in Pakistan 182
Honeywell International Acquires Research Chemicals Business from Sigma-Aldrich 183
Schussler Novachem to Acquire Lab Equipment and Production Units from Merck 185
Eurofins Scientific Acquires Assets of Discovery and Development Solutions Business of Merck 186
Kaneq Pharma Acquires Intellectual Property for PTP-1B Insulin-Sensitizer Program from Merck 187
Corpak MedSystems Acquires Gastroenterology Sales And Distribution Operations Of Merck Serono 188
Acquisition 189
Merck Sante Sells 4.74% Stake in Poxel 189
Merck to Acquire Natrix Separations 190
Merck Sells Bangalore Genei for USD1.5 Million 191
Merck Acquires Sigma-Aldrich for USD17 Billion 192
Johnson Matthey Acquires SAFC Pharmorphix from Sigma-Aldrich 194
Merck And BASF Acquire Majority Stake In Innovation Lab 195
Albany Molecular Research Acquires Cedarburg Pharmaceuticals 196
EMD Millipore Completes Acquisition Of Biochrom, Provider Of Cell Culture Media Products 198
Sigma-Aldrich Acquires Research Organics, Manufacturer Of Biochemicals 199
Proxy Labs Acquires MicroSafe Laboratories From Millipore 200
Merck KGaA – Key Competitors 201
Merck KGaA – Key Employees 202
Merck KGaA – Locations And Subsidiaries 203
Head Office 203
Other Locations & Subsidiaries 203
Recent Developments 213
Strategy And Business Planning 213
Oct 17, 2018: Merck Inaugurates State-of-the-art Pharma Packaging Center in Darmstadt 213
Jun 05, 2018: Merck Brings Biotechs Closer to Drug Therapy Production and Commercialization 214
Oct 11, 2017: Merck Opens New Life Science Center for Scientific Collaboration 215
Oct 11, 2017: MilliporeSigma Opens New Life Science Center in Massachusetts for Scientific Collaboration 216
Sep 28, 2017: Merck On Course To Achieve Objectives for 2018 217
Sep 22, 2017: Merck Opens China’s First BioReliance End-to-End Biodevelopment Center in Shanghai 219
Sep 13, 2017: Merck Expands Celonic’s Upstream Capabilities with Mobius Single-use Bioreactors 220
Sep 05, 2017: Merck Prepares Strategic Options for the Consumer Health Business 221
Jun 29, 2017: Merck Expands Packaging Capacity at Swiss Biotech Manufacturing Site of Aubonne 222
Jun 20, 2017: Merck Ventures Creates New Immuno-Oncology Company iOnctura 223
May 16, 2017: Merck: Optimizing the Further Development of the Darmstadt Site 224
May 12, 2017: Merck Opens First Joint Bioprocess Scale-up Lab with Stelis Biopharma in India 225
Apr 20, 2017: Merck Provides Upgraded Manufacturing Capabilities to BioInvent with Single-use Mobius Bioreactors 226
Jan 10, 2017: Merck Expands End-to-End Biodevelopment Centers in North America, China and Europe 227
Financial Announcements 228
Feb 02, 2018: Merck Announces Fourth-Quarter and Full-Year 2017 Financial Results 228
Nov 09, 2017: Merck Confirms Outlook for 2017 Despite a Challenging Third Quarter 233
Aug 03, 2017: Q2 2017: Merck Sets Course for Future Growth 235
May 18, 2017: Merck Continues to Grow Profitably in the First Quarter 237
Corporate Communications 239
Jan 26, 2018: Merck Appoints Dirk Toepfer as Chief Information Officer 239
Dec 15, 2017: Petra Wicklandt Appointed Head of Corporate Affairs at Merck 240
Dec 12, 2017: Allan Gabor Takes Over the Leadership of Merck in China 241
Dec 06, 2017: Merck: Resignation of Managing Director 242
Aug 03, 2017: Executive Board Changes at Merck 243
Legal and Regulatory 244
Feb 23, 2018: Fish & Richardson Wipes Out $2.5 Billion Patent Verdict Against Gilead Sciences on JMOL 244
Apr 19, 2017: Merck Earns Accreditation for Quality Control of Culture Media 245
Government and Public Interest 246
Jun 12, 2018: Merck Drives Thought Leadership in Ethical Gene Editing 246
Mar 19, 2018: The Pistoia Alliance Calls for Greater Life Sciences Collaboration to Build the ‘Lab of the Future’ 247
Nov 10, 2017: Merck Announced as 2017 “Simply the Best Award” Honoree at the Bonnie J. Addario Lung Cancer Foundation’s “Simply the Best” Dinner and Gala 248
Oct 26, 2017: Merck Announces Recipients of €1 Million Grant for Multiple Sclerosis Innovation at ECTRIMS 2017 249
Sep 18, 2017: Merck Announces Recipients of the Grant for Growth Innovation 2017 250
Sep 10, 2017: Merck ‘Grant for Oncology Innovation’ awards recognize recipients for pushing boundaries in oncology research 251
Jul 06, 2017: Merck Biopharma Innovation Cup 2017 252
Jul 05, 2017: Merck Awards €1.25 Million to Research Projects Through its 2017 Grant for Fertility Innovation 253
Jul 05, 2017: Merck KGaA, Darmstadt, Germany Awards €1.25 Million to Research Projects Through its 2017 Grant for Fertility Innovation 254
Jan 23, 2017: Merck Announces Emerging Biotech Grant Program Winners 255
Product News 256
Nov 13, 2017: Merck Introduces Stericup Quick Release System for Improved Cell Culture Filtration 256
Oct 30, 2017: Merck: Product Announcement: Process Solutions 257
10/20/2017: Merck Presents New Clinical Data on Evobrutinib at 2017 ACR/ARHP Annual Meeting 258
10/18/2017: Merck to Present New Data on Evobrutinib at ECTRIMS 2017 260
Oct 12, 2017: 10 SU2C Catalyst Clinical Trials Launched 262
Sep 20, 2017: Merck Introduces Eshmuno P Anti-A and Anti-B Chromatography Resins for Enhancement of Plasma-Derived Immunoglobulin 264
06/23/2017: Cladribine Tablets Receives Positive CHMP Opinion for Treatment of Relapsing Forms of Multiple Sclerosis 265
Jun 08, 2017: BioMed X and Merck launch two new crowdsourcing projects in the fields of cancer research and biologics manufacturing 266
05/22/2017: Novel Nanobody To Start Clinical Development In Osteoarthritis Ablynx To Receive €15 Million Milestone Payment 267
May 17, 2017: Merck Develops Alternative CRISPR Genome Editing Method 268
May 15, 2017: Merck Launches Industry’s First Off-the-Shelf Cell Culture Media for Perfusion Processes 269
04/28/2017: Investigational Cladribine Tablets Data Show Greater Treatment Effect in Relapsing MS Patients at a Higher Risk of Disease Progression 270
Apr 27, 2018: Merck Advances Cell Analysis with New Benchtop Flow Cytometer with Camera Detection 271
04/21/2017: Merck to Present Data on Cladribine at AAN 2017 272
Apr 03, 2017: Merck Wins Scotland’s Life Science Award for Excellence in Community Engagement 275
Mar 06, 2017: Merck Advances Lab Water Purification Technology with Milli-Q(R) IQ 7000 System 276
Feb 13, 2018: Merck Launches Viresolve Barrier Capsule Filters to Protect Against Bioreactor Contamination 277
Clinical Trials 278
Jun 04, 2018: Merck Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018 278
May 16, 2018: Merck to Present M7824 Data at ASCO 2018 280
Apr 17, 2018: Merck to Present Data for Osteoarthritis Drug Candidate M1673 at OARSI 2018 World Congress 281
Apr 17, 2018: Merck to Present Data on its ADAMTS-5 inhibiting nanobody M6495 at OARSI 2018 World Congress 283
Apr 17, 2018: Merck to Present on Sprifermin at OARSI 2018 World Congress 285
Jan 16, 2018: Merck Presents Data on Bifunctional Immunotherapy M7824 at ASCO 2018 Gastrointestinal Cancers Symposium 287
Nov 04, 2017: Merck KGaA, Darmstadt, Germany Presents Late Breaking Clinical Data from Phase II Trial of Sprifermin for Osteoarthritis Disease Modification 289
Oct 20, 2017: Merck Presents New Data on Sprifermin at 2017 ACR/ARHP Annual Meeting 290
Sep 12, 2017: Merck Advances Immunology Pipeline with Evobrutinib (Brutons Tyrosine Kinase Inhibitor) 292
Jun 26, 2017: Data Provide Additional Insight into the Mode of Action of MAVENCLAD (Cladribine Tablets) in Patients with Relapsing MS 293
Feb 09, 2017: Cladribine Tablets Significantly Reduced Brain Atrophy in Patients with Multiple Sclerosis 294
Other Significant Developments 295
Aug 06, 2018: Merck Foundation Continues to Strengthen Their Merck Cancer Access Program in Gambia, Lesotho, Botswana and Zimbabwe 295
Feb 21, 2018: Merck Invests Additional €40 Million to Enhance Manufacturing and Distribution in Asia 296
Dec 11, 2017: Merck Signs Distribution Agreement with Avanti Polar Lipids 297
Oct 03, 2017: Merck Invests € 35 Million in its Italian Biotech Manufacturing Site of Bari 298
Sep 27, 2017: Merck Provides Update on EU’s Horizon 2020 Program to Improve Biopharmaceutical Downstream Processing 299
Jul 12, 2017: Merck Refines Western European Life Science Production Site Network 300
Mar 21, 2017: Merck Introduces Mobius MyWay Portfolio for Customized Single-Use Assemblies 301
Mar 21, 2017: Merck Accelerator Hits New Peak of Applications 302
Mar 09, 2017: Merck Generates Record Sales and Continues to Grow Profitably in 2016 303
Feb 15, 2017: Merck to Supply Single-use Systems to WuXi Biologics for Non-GMP Pilot Plant in Shanghai 305
Jan 18, 2017: Merck Launches First Commercial Screening Service to Predict Multiple Sources of DNA Damage 306
Appendix 307
Methodology 307
About GlobalData 307
Contact Us 307
Disclaimer 307

List of Tables
Merck KGaA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 13
Merck KGaA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 14
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 15
Merck KGaA, Deals By Therapy Area, 2012 to YTD 2018 16
Merck KGaA, Medical Devices Deals, 2012 to YTD 2018 18
Merck KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 19
Merck KgaA Acquires SevenSeas Original Brand 28
Sutro Biopharma Raises USD85.4 Million in Series E Financing 29
SerImmune Raises USD8 Million in Venture Financing 31
TocopheRx Raises US$3.3 Million In Seed Financing 32
Kyowa Hakko Kirin Enters into Agreement with Merck and Pfizer 33
Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 34
Accelerated Cure Project Enters into Co-Development Agreement with EMD Serono 35
Immutep Enters into Agreement with Merck and Pfizer 36
Checkmate Pharma Enters into Partnership with Merck and Pfizer 37
Leap Therapeutics Enters into Co-Development Agreement with Merck and Pfizer 38
Vyriad Enters into Collaboration Agreement with Merck and Pfizer 39
Merck Enters into Co-Development Agreement with Xian-Janssen Pharma 40
Merck Enters into Development Agreement with SFJ Pharma 41
Forty Seven Enters into Agreement with Merck 42
Merck Enters into Agreement with Avanti Lipids Polar 43
Neon Therapeutics Enters into Agreement with Merck 44
Orexigen Therapeutics Enters into Agreement with Merck KGaA 45
MilliporeSigma to Enter into Agreement with Samsung Biologics 46
Phosplatin Therapeutics Enters into Agreement with Pfizer and Merck 47
MilliporeSigma Enters into Agreement with Angiex 48
Merck Enters into Partnership with Angiex 49
Millipore Enter into Partnership with Baylor College of Medicine and Texas Children's Hospital 50
Acino International Enters into Distribution Agreement with Merck 51
Cancer Research Technology Enters into Agreement with Merck 52
eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 53
SerImmune Enters into R&D Agreement with Merck 54
Human Longevity Enters into Agreement with Merck 55
F-star Biotech Enters into Partnership with Merck 56
EpiThany Enters into Agreement with Merck and Pfizer 57
VAXIMM Enters into Agreement with Merck and Pfizer 58
Avillion Enters into Co-Development Agreement with Merck 59
Merck Enters into Agreement with Palantir Technologies 60
EMD Serono Enters into Agreement with University of Texas MD Anderson Cancer Center 61
F. Hoffmann-La Roche Expands its Distribution Agreement with MilliporeSigma 62
Evotec Partners with Merck 63
BioMed X Enters into Agreement with Merck 64
Debiopharm Partners with Merck and Pfizer 65
Transgene Enters into Agreement with Merck and Pfizer 66
Vaccinex Enters into Agreement with Merck 67
PCAS Enters into Distribution Agreement with MilliporeSigma 68
MilliporeSigma Enters into Research Agreement with International Vaccine Institute 69
Selvita Enters into Agreement with Merck 70
Merck Enters into Agreement with University of Buea 71
Merck, Pfizer and Verastem Enter into Agreement 72
Merck Enters into Research Agreement with European Molecular Biology Labs 73
Merck, Pfizer and Syndax Pharma Enter into Agreement 74
Selvita Enters into Development and Commercialization Agreement with Merck 75
Biothera Pharma Expands Agreement with Merck 76
Sigma-Aldrich Enters into Agreement with Sanger Institute 77
Sigma-Aldrich Enters into Distribution Agreement with IROA Technologies 78
Nippon Shinyaku Enters into Co-Promotion Agreement with Merck Serono 79
Merck Serono Enters into Co-Development Agreement with Genea Biomedx and Illumina 80
Aeterna Zentaris Enters into Agreement with EMD Serono 81
Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 82
Lucigen Enters into Distribution Agreement with Sigma-Aldrich 83
Merck Serono Enters into Co-Development Agreement with MMV 84
Sigma-Aldrich Enters into Distribution Agreement with Roche 85
Merck Enters into Development Agreement with Precision Biologics 86
Indi Molecular Enters into Co-Development Agreement with Sigma-Aldrich 87
Pfizer Enters into Co-Development Agreement with Merck 88
BioSilta Enters into Co-Marketing Agreement with Sigma-Aldrich 90
Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 91
Hutchison China MediTech Enters into Co-Promotion Agreement with Merck Serono for Cardiovascular Drug Products 92
Merck Plans to Enter into Co-Development Agreement for Anti-PD-L1 93
Lupin Enters into Co-Development Agreement with Merck Serono 94
Merck Serono Extends R&D Agreement with San Raffaele 95
Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 96
Merck Serono Enters into Co-Development Agreement with Sysmex Inostics 97
Bionovis Enters into Agreement with Merck 98
EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 99
EMD Millipore Enters Into Co-Development Agreement With Promethera Biosciences 100
KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 101
Biopharm Enters Into Research Agreement With Merck Serono 102
Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 103
Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 104
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 105
Sigma-Aldrich Enters Into Distribution Agreement With Paragon Scientific 106
Gyros And EMD Millipore Enter Into Agreement To Develop And Commercialize Immunoassay Kits 107
Isu Abxis Enters into Co-Development Agreement with Merck 108
Luminex Extends Distribution Agreement With EMD Millipore 109
Alchemia Enters Into Collaboration Agreement with Merck Serono 110
Merck Serono Enters Into Clinical Development Agreement With Quintiles Transnational 111
Sigma Life Science Enters Into Distribution Agreement With The Culture Collections of Public Health England 112
Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 113
Merck Enters Into Co-Development Agreement With Nordic Bioscience For Sprifermin 114
Merck Serono Enters Into Co-Development Agreement With Feinstein Institute For Therapy Of Inflammatory Diseases 115
EMD Millipore Enters Into Co-Development Agreement With Sistemic For Stem Cell Markers 116
AB Sciex Enters Into Distribution Agreement With Sigma-Aldrich For Sciex Ichemistry Solutions 117
EMD Millipore Enters Into Co-Marketing Agreement With Julphar Diabetes For Recombinant Human Insulin 118
Sigma Life Science Expands Agreement With Autism Speaks To Develop Rat Models For Autism Research 119
Sigma Life Science Enters Into Co-Marketing Agreement With Axiogenesis 120
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 121
TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 122
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 124
Genovis Enters Into Distribution Agreement With Sigma-Aldrich 125
Dr. Reddy’s Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 126
EMD Millipore Enters Into Distribution Agreement With Ventria Bioscience 127
EMD Millipore Enters Into Co-Development Agreement With Centre for Commercialization of Regenerative Medicine 128
Mapi Pharma Amends Co-Development Agreement With Merck 129
TriLink BioTechnologies Enters Into Distribution Agreement With Sigma-Aldrich 130
Isotopen Enters into Option Agreement to License for Folate Receptor with Merck 131
Merck Enters into Licensing Agreement with Nerviano Medical Sciences 132
Selexis Enters into Licensing Agreement with Merck KGaA 133
Merck Enters into Licensing Agreement with Domain Therapeutics 134
Merck Enters into Licensing Agreement with Vertex Pharma 135
Relief Therapeutics Enters into Licensing Agreement with Merck Serono 136
ObsEva Enters into Licensing Agreement with Merck Serono for OBE022 137
EMD Millipore Enters into Licensing Agreement with Singulex 138
Intrexon Enters into Licensing Agreement with Merck Serono 139
Allergopharma Enters into Licensing Agreement with S-TARget therapeutics 140
EMD Serono Amends its Licensing Agreement with Mersana Therapeutics 141
MorphoSys Enters into Licensing Agreement with Merck Serono 142
Merck Enters Into Licensing Agreement With Spanish National Cancer Research Centre 143
Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 144
ObsEva Enters Into Licensing Agreement With Merck Serono 145
Plasticell Enters Into Licensing Agreement With EMD Millipore For Xeno-Free Osteogenic Medium 146
Merck Enters into Licensing Agreement with Weizmann Institute of Science 147
Qualyst Transporter Solutions Enters into Licensing Agreement with BioReliance 148
Sigma Life Science Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 149
EMD Serono Enters into Licensing Agreement with Sutro Biopharma 150
Sage Labs Enters Into Licensing Agreement With Caribou Biosciences 151
Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 152
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 153
Sigma-Aldrich Enters Into Licensing Agreement With Scripps Research Institute For Research Reagents 155
Cellular Dynamics Enters Into Licensing Agreement With Life Technologies And Sigma-Aldrich 156
Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 157
Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 158
EMD Millipore Enters Into Licensing Agreement With iPS Academia For Stem Cell Patents 159
Materia Extends Licensing Agreement With Sigma Aldrich 160
PDS Biotechnology Enters Into Licensing Agreement With Merck For Versamune 161
Ligand Pharma Enters Into Licencing Agreement With Merck 162
Sigma-Aldrich Enters Into Licensing Agreement With University of Illinois 163
EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 164
Sigma Life Science Enters Into Licensing Agreement With Kyoto University 165
KalVista Pharma Raises USD9.1 Million in Private Placement of Shares 166
iOnctura Spin Out from Merck and Cancer Research Technology 167
Merck Raises USD801.4 Million in Private Placement of 0.23% Bonds Due 2017 168
Merck Raises USD916 Million in Private Placement of 0.75% Bonds Due 2019 169
Merck Raises USD629.7 Million in Private Placement of 1.375% Bonds Due 2022 170
Merck Raises USD1 Billion in Private Placement of 2.95% Notes Due 2022 171
Merck Raises USD750 Million in Private Placement of 2.4% Notes Due 2020 172
Merck Raises USD400 Million in Private Placement of 1.7% Notes Due 2018 173
Merck Raises USD250 Million in Private Placement of Floating Rate Notes Due 2017 174
Merck Raises USD1.6 Billion in Private Placement of 3.25% Notes Due 2025 175
Merck Raises USD1.2 Billion in Private Placement of 2.625% Bonds Due 2074 176
Merck Raises USD614 Million in Private Placement of 3.375% Bonds Due 2074 177
Procter & Gamble Receives Approval to Acquire 51.8% Stake in Consumer Health Business from Merck for USD4.2 Billion 178
Fresenius Acquires Biosimilars Business from Merck for USD703 Million 180
Zydus Healthcare Acquires Six Brands from Merck 181
Martin Dow Acquires Merck Operations in Pakistan 182
Honeywell International Acquires Research Chemicals Business from Sigma-Aldrich 183
Schussler Novachem to Acquire Lab Equipment and Production Units from Merck 185
Eurofins Scientific Acquires Assets of Discovery and Development Solutions Business of Merck 186
Kaneq Pharma Acquires Intellectual Property for PTP-1B Insulin-Sensitizer Program from Merck 187
Corpak MedSystems Acquires Gastroenterology Sales And Distribution Operations Of Merck Serono 188
Merck Sante Sells 4.74% Stake in Poxel 189
Merck to Acquire Natrix Separations 190
Merck Sells Bangalore Genei for USD1.5 Million 191
Merck Acquires Sigma-Aldrich for USD17 Billion 192
Johnson Matthey Acquires SAFC Pharmorphix from Sigma-Aldrich 194
Merck And BASF Acquire Majority Stake In Innovation Lab 195
Albany Molecular Research Acquires Cedarburg Pharmaceuticals 196
EMD Millipore Completes Acquisition Of Biochrom, Provider Of Cell Culture Media Products 198
Sigma-Aldrich Acquires Research Organics, Manufacturer Of Biochemicals 199
Proxy Labs Acquires MicroSafe Laboratories From Millipore 200
Merck KGaA, Key Competitors 201
Merck KGaA, Key Employees 202
Merck KGaA, Subsidiaries 203

List of Figures
Merck KGaA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 13
Merck KGaA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 14
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 15
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 16
Merck KGaA, Medical Devices Deals, 2012 to YTD 2018 18

★海外企業調査レポート[Merck KGaA (MRK)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • AU Optronics Corp.：企業の戦略・SWOT・財務分析
    AU Optronics Corp. - Strategy, SWOT and Corporate Finance Report Summary AU Optronics Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • The State Export-Import Bank of Ukraine：企業の戦略・SWOT・財務情報
    The State Export-Import Bank of Ukraine - Strategy, SWOT and Corporate Finance Report Summary The State Export-Import Bank of Ukraine - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Ameritas Mutual Holding Company：企業の戦略的SWOT分析
    Ameritas Mutual Holding Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • PT Kideco Jaya Agung：企業の戦略・SWOT・財務情報
    PT Kideco Jaya Agung - Strategy, SWOT and Corporate Finance Report Summary PT Kideco Jaya Agung - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • HSH Nordbank Private Banking：企業の戦略・SWOT・財務情報
    HSH Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report Summary HSH Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Meyer Burger Technology AG (MBTN)：企業の財務・戦略的SWOT分析
    Meyer Burger Technology AG (MBTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Verizon Connect：企業の戦略的SWOT分析
    Verizon Connect - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • AvidBiotics Corp-製薬・医療分野：企業M&A・提携分析
    Summary AvidBiotics Corp (AvidBiotics) is a healthcare company that develops non-antibody proteins targeting cancer, bacteria and virus-infected cells. The company develops a portfolio of therapeutic protein candidates and protein engineering platforms which include avidocin proteins, mica-body prot …
  • Bosch Sensortec GmbH：企業の戦略的SWOT分析
    Bosch Sensortec GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Gulf Power Co：発電所・企業SWOT分析
    Gulf Power Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exec …
  • SK Biopharmaceuticals Co Ltd-製薬・医療分野：企業M&A・提携分析
    Summary SK Biopharmaceuticals Co Ltd (SK Biopharmaceuticals), a subsidiary of SK Holdings Co Ltd is a developer of drug candidates. The company develops and markets innovative drugs for the treatment of central nervous system. It offers plumiaz, SKL-N05 and JZP-110; YKP3089, relenopride, SKL-PD, SKL …
  • Ck Hutchison Holdings Ltd：企業の戦略・SWOT・財務分析
    Ck Hutchison Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Ck Hutchison Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Berkshire Hathaway Inc：戦略・SWOT・企業財務分析
    Berkshire Hathaway Inc - Strategy, SWOT and Corporate Finance Report Summary Berkshire Hathaway Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Trovagene Inc (TROV)-医療機器分野：企業M&A・提携分析
    Summary Trovagene Inc (Trovagene) is a development stage molecular diagnostic company focusing on the development and commercialization of proprietary molecular genetic detection technologies for screening and monitoring cancer and other diseases. Its product portfolio includes liquid biopsy tests t …
  • Air Products and Chemicals Inc (APD)：企業の財務・戦略的SWOT分析
    Air Products and Chemicals Inc (APD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Microsemi Corp：企業の戦略的SWOT分析
    Microsemi Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • VidaCaixa, S.A.U. de Seguros y Reaseguros：企業の戦略・SWOT・財務情報
    VidaCaixa, S.A.U. de Seguros y Reaseguros - Strategy, SWOT and Corporate Finance Report Summary VidaCaixa, S.A.U. de Seguros y Reaseguros - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Matrix IT Ltd (MTRX)：企業の財務・戦略的SWOT分析
    Matrix IT Ltd (MTRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Avantis Medical Systems Inc：医療機器：M&Aディール及び事業提携情報
    Summary Avantis Medical Systems Inc (AMS) is a medical device company that provides visualization technology solutions. The company uses its technology platform and software analysis for the screening and early detection of cancer. It offers products such as single camera colonoscopy devices and thi …
  • Indianapolis Power & Light Co：企業の戦略的SWOT分析
    Indianapolis Power & Light Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆